Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis.

ABSTRACT:

Background

Glioblastoma (GBM) is a highly aggressive cancer with poor prognosis that needs better treatment modalities. Moreover, there is a lack of reliable biomarkers to predict the response and outcome of current or newly designed therapies. While several molecular markers have been proposed as potential biomarkers for GBM, their uptake into clinical settings is slow and impeded by marker heterogeneity. Detailed assessment of prognostic and predictive value for biomarkers in well-defined clinical trial settings, if available, is scattered throughout the literature. Here we conducted a systematic review and meta-analysis to evaluate the prognostic and predictive significance of clinically relevant molecular biomarkers in GBM patients.

Material and methods

A comprehensive l

SUBMITTER: Sareen H 

PROVIDER: S-EPMC9408540 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature